We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > IPI-549

News List

Infinity gets FDA fast track status for IPI-549, Opdivo combo in urothelial cancer pharmaceutical-business-review
March 30, 2020
Infinity Pharmaceuticals said that IPI-549 in combination with nivolumab (Opdivo) has been given the fast track designation from the US Food and Drug Administration (FDA).
Infinity Announces Start of Two IPI-549 Trials for Solid Tumors americanpharmaceuticalreview
September 05, 2019
Infinity Pharmaceuticals announced the initiation of two clinical trials for IPI-549, a first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through ...
Bristol-Myers Squibb and Infinity to collaborate on Opdivo (nivolumab) plus IPI-549 solid tumours study europeanpharmaceuticalreview
May 08, 2019
Bristol-Myers Squibb and Infinity will collaborate on a solid tumours trial to evaluate Bristol-Myers Squibb’s Opdivo in combination with Infinity’s…